Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 3/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.73 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.73 |
| ▸ | BLM | P54132 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.73 |
| ▸ | HTT | P42858 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Metioprim SCHEMBL30659007 | 1.00 | DHFR (0.73) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL11548085 | 0.91 | DHFR (0.65) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL11544522 | 0.91 | DHFR (0.65) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL11260435 | 0.87 | DHFR (0.70) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Aditeren SCHEMBL1230789 | 0.86 | DHFR (0.81) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL11257800 | 0.85 | SMN1; SMN2 (0.64) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| SCHEMBL9284945 | 0.85 | DHFR (0.79) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL2637561 | 0.85 | DHFR (1.00) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Trimethoprim SCHEMBL24506 | 0.85 | DHFR (1.00) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 | |
| Aditeren SCHEMBL10676774 | 0.85 | DHFR (0.79) | DHFRMEN1SLC22A1ALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4536217-A1 | CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS | Fleurir Abx LLC (US) | 2025-04-16 | — | — | EP | claimed |
| US-20240293434-A1 | COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS | FLEURIR ABX LLC (US) | 2024-09-05 | — | — | US | claimed |
| WO-2023239822-A1 | CO-AGENTS AS THERAPY AGAINST ANAEROBIC PATHOGENS | FLEURIR ABX LLC (US) | 2023-12-14 | — | — | WO | claimed |
| US-20230398101-A1 | Co-agents as Therapy Against Anaerobic Pathogens | FLEURIR ABX LLC (US) | 2023-12-14 | — | — | US | claimed |
| US-20220169680-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES (CN) | 2022-06-02 | — | — | US | claimed |
| EP-3923953-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2021-12-22 | — | — | EP | claimed |
| EP-3912989-A1 | CELL-PENETRATING PEPTIDE BASED ON INFLUENZA VIRUS M2 PROTEIN | Institute of Basic Medical Sciences Chinese Academy of Medical Sciences (CN) | 2021-11-24 | — | — | EP | claimed |
| WO-2020168358-A2 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-08-20 | — | — | WO | claimed |
| US-20200253994-A1 | PYRIMIDINE DERIVATIVE CONTAINING COMPOSITIONS | CHEMISTRYRX (US) | 2020-08-13 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-1578434-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | Point Therapeutics, Inc. (US) | 2005-09-28 | — | — | EP | claimed |
| US-20040131628-A1 | Nucleic acids for the treatment of disorders associated with microorganisms | BRATZLER ROBERT L (US) | 2004-07-08 | — | — | US | claimed |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | POINT THERAPEUTICS, INC. | 2004-04-22 | — | — | US | claimed |
| WO-2004004658-A2 | METHODS AND COMPOSITIONS RELATING TO ISOLEUCINE BOROPROLINE COMPOUNDS | POINT THERAPEUTICS, INC. (US) | 2004-01-15 | — | — | WO | claimed |
| US-4599416-A | Process for the preparation of aqueous solutions of potentiated sulfonamides | HOFFMANN-LA ROCHE INC. (US) | 1986-07-08 | — | — | US | claimed |
| EP-0037501-B1 | PHARMACEUTICAL PREPARATIONS AND MANUFACATURE | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1984-07-18 | — | — | EP | claimed |
| EP-0003212-B1 | 2.4-DIAMINO-5-BENZYLPYRIMIDINES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR PREPARATION | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1982-03-17 | — | — | EP | claimed |
| EP-0037501-A1 | Pharmaceutical preparations and manufacature | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1981-10-14 | — | — | EP | claimed |
| US-4180578-A | 2,4-Diamino-5-(4'-methylthio)benzylpyrimidenes, compounds, compositions and method of use | Ludwig Heumann, & Co. GmbH (DE) | 1979-12-25 | — | — | US | claimed |
| EP-0003212-A1 | 2.4-Diamino-5-benzylpyrimidines, pharmaceutical compositions containing them and their preparation | F. HOFFMANN-LA ROCHE & CO. Aktiengesellschaft (CH) | 1979-08-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293434-A1 | COMBINATION THERAPY EFFECTIVE AGAINST MICROORGANISMS, INCLUDING DRUG RESISTANT MICROORGANISMS | SLC11A2, MYD88, FPR2 | DHFR 7/4885MEN1 957/4885SLC22A1 3025/4885 |
| US-20040077601-A1 | Methods and compositions relating to isoleucine boroproline compounds | BCAT1, BCAT2, APOB | DHFR 69/4885MEN1 1014/4885SLC22A1 1246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.